Cargando…
Current and Future Neuropharmacological Options for the Treatment of Essential Tremor
BACKGROUND: Essential Tremor (ET) is likely the most frequent movement disorder. In this review, we have summarized the current pharmacological options for the treatment of this disorder and discussed several future options derived from drugs tested in experimental models of ET or from neuropatholog...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457404/ https://www.ncbi.nlm.nih.gov/pubmed/31976837 http://dx.doi.org/10.2174/1570159X18666200124145743 |
_version_ | 1783575987234013184 |
---|---|
author | Alonso-Navarro, Hortensia García-Martín, Elena Agúndez, José A.G. Jiménez-Jiménez, Félix J. |
author_facet | Alonso-Navarro, Hortensia García-Martín, Elena Agúndez, José A.G. Jiménez-Jiménez, Félix J. |
author_sort | Alonso-Navarro, Hortensia |
collection | PubMed |
description | BACKGROUND: Essential Tremor (ET) is likely the most frequent movement disorder. In this review, we have summarized the current pharmacological options for the treatment of this disorder and discussed several future options derived from drugs tested in experimental models of ET or from neuropathological data. METHODS: A literature search was performed on the pharmacology of essential tremors using PubMed Database from 1966 to July 31, 2019. RESULTS: To date, the beta-blocker propranolol and the antiepileptic drug primidone are the drugs that have shown higher efficacy in the treatment of ET. Other drugs tested in ET patients have shown different degrees of efficacy or have not been useful. CONCLUSION: Injections of botulinum toxin A could be useful in the treatment of some patients with ET refractory to pharmacotherapy. According to recent neurochemical data, drugs acting on the extrasynaptic GABA(A) receptors, the glutamatergic system or LINGO-1 could be interesting therapeutic options in the future. |
format | Online Article Text |
id | pubmed-7457404 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-74574042020-12-01 Current and Future Neuropharmacological Options for the Treatment of Essential Tremor Alonso-Navarro, Hortensia García-Martín, Elena Agúndez, José A.G. Jiménez-Jiménez, Félix J. Curr Neuropharmacol Article BACKGROUND: Essential Tremor (ET) is likely the most frequent movement disorder. In this review, we have summarized the current pharmacological options for the treatment of this disorder and discussed several future options derived from drugs tested in experimental models of ET or from neuropathological data. METHODS: A literature search was performed on the pharmacology of essential tremors using PubMed Database from 1966 to July 31, 2019. RESULTS: To date, the beta-blocker propranolol and the antiepileptic drug primidone are the drugs that have shown higher efficacy in the treatment of ET. Other drugs tested in ET patients have shown different degrees of efficacy or have not been useful. CONCLUSION: Injections of botulinum toxin A could be useful in the treatment of some patients with ET refractory to pharmacotherapy. According to recent neurochemical data, drugs acting on the extrasynaptic GABA(A) receptors, the glutamatergic system or LINGO-1 could be interesting therapeutic options in the future. Bentham Science Publishers 2020-06 2020-06 /pmc/articles/PMC7457404/ /pubmed/31976837 http://dx.doi.org/10.2174/1570159X18666200124145743 Text en © 2020 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Alonso-Navarro, Hortensia García-Martín, Elena Agúndez, José A.G. Jiménez-Jiménez, Félix J. Current and Future Neuropharmacological Options for the Treatment of Essential Tremor |
title | Current and Future Neuropharmacological Options for the Treatment of Essential Tremor |
title_full | Current and Future Neuropharmacological Options for the Treatment of Essential Tremor |
title_fullStr | Current and Future Neuropharmacological Options for the Treatment of Essential Tremor |
title_full_unstemmed | Current and Future Neuropharmacological Options for the Treatment of Essential Tremor |
title_short | Current and Future Neuropharmacological Options for the Treatment of Essential Tremor |
title_sort | current and future neuropharmacological options for the treatment of essential tremor |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457404/ https://www.ncbi.nlm.nih.gov/pubmed/31976837 http://dx.doi.org/10.2174/1570159X18666200124145743 |
work_keys_str_mv | AT alonsonavarrohortensia currentandfutureneuropharmacologicaloptionsforthetreatmentofessentialtremor AT garciamartinelena currentandfutureneuropharmacologicaloptionsforthetreatmentofessentialtremor AT agundezjoseag currentandfutureneuropharmacologicaloptionsforthetreatmentofessentialtremor AT jimenezjimenezfelixj currentandfutureneuropharmacologicaloptionsforthetreatmentofessentialtremor |